Management of atrial fibrillation for older people with frailty: a systematic review and meta-analysis

Chris Wilkinson^{1,2}, Oliver Todd³, Andrew Clegg³, Chris P Gale^{1,2}, Marlous Hall¹

¹Department of Clinical and Population Sciences, Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Worsley Building, Level 11, Clarendon Way, Leeds, LS2 9JT, UK

²York Teaching Hospital NHS Foundation Trust, Wiggington Road, York, YO31 8HE, UK

³Academic Unit of Eldery Care and Rehabilitation, Bradford Institute for Health Research, University of Leeds, Bradford Royal Infirmary, Duckworth Lane, Bradford, BD9 6RJ, UK

Address correspondence to: Dr Chris Wilkinson. Tel: +44 (0) 1 3 343 8905; Fax: +44(0) 1 3 343 4877. Email: umcgw@leeds.ac.uk

Abstract

Background: despite a large and growing population of older people with frailty and atrial fibrillation (AF), there is a lack of guidance on optimal AF management in this high-risk group.

Objective: to synthesise the existing evidence base on the association between frailty, AF and clinical outcomes.

Methods: a systematic review of studies examining the association between validated measures of frailty, AF and clinical outcomes, and meta-analysis of the association between frailty and oral anticoagulation (OAC) prescription.

Results: twenty studies (30,883 patients) were included, all observational. Fifteen were in hospital, four in the community, one in nursing care. Risk of bias was low-to-moderate. AF prevalence was 3%–38%. In people with AF, frailty was associated with increased stroke incidence, all-cause mortality, symptom severity and length of hospital stay.

Meta-analysis of six studies showed frailty was associated with decreased OAC prescription at hospital admission (pooled adjusted OR 0.45 [95%CI 0.22–0.93], three studies), but not at discharge (pooled adjusted OR 0.40 [95%CI 0.13–1.23], three studies). A community-based study showed increased OAC prescription associated with frailty (OR 2.33 [95%CI 1.03–5.23]).

Conclusion: frailty is common, and associated with adverse clinical outcomes in patients with AF. There is evidence of an association between frailty status and OAC prescription, with different direction of effect in community compared with hospital cohorts. Despite the majority of care for older people being provided in the community, there is a lack of evidence on the association between frailty, AF, anticoagulation and clinical outcomes to guide optimal care in this setting.

Keywords

atrial fibrillation, frailty, anticoagulation, systematic review, older people

Key points

- Older people with frailty and AF are at risk of worse clinical outcomes.
- Anticoagulation of older people with frailty and AF is an under-researched area.
- Frailty is associated with lower rates of anticoagulation in patients with AF who are admitted to hospital.

Management of atrial fibrillation for older people with frailty

Introduction

The prevalence of atrial fibrillation (AF) increases with age, affecting up to 4.2% of those aged 60–70 years and 17% of those aged 80 years or older [1]. Around one in four hospitalised older people have AF [2], so management of AF in older people is a commonly encountered clinical challenge. Old age is a risk factor for thromboembolic outcomes of AF, but there is evidence for a risk-treatment paradox whereby older patients who are at highest risk of complications of AF, including stroke, are not more likely to be prescribed oral anticoagulation (OAC) [3–6]. This appears to be related to fear of iatrogenic harm and a lack of confidence in the evidence of benefit in an older population [7, 8].

It is increasingly recognised that frailty is a more useful approach to guide care in older people than chronological age. It is a condition characterised by loss of biological reserves, failure of homeostatic mechanisms and vulnerability to a range of adverse outcomes [9], and can help guide more individualised treatments with advancing multi-morbidity and polypharmacy [10]. The prevalence of patients with frailty and AF is growing [11], making optimal management an important goal for older people, clinicians, health services and social care [12–14].

National Institute for Health and Care Excellence (NICE) guidance recommends using the CHA2DS2-VASc score to identify individuals with a high ischaemic stroke risk, and offering OAC to men with a score of 1, and to men or women with a score of 2 or above [15]. However, the studies on which the guidance was based did not explicitly assess frailty. Assessment and modification of bleeding risk factors using the HAS-BLED score is recommended, but there may be additional considerations in a population with frailty such as a higher risk of bleeding and falls [16]. The optimal treatment strategy for people with AF and frailty is therefore unclear, as there is evidence of increased risk of stroke and of treatment related harms. Whilst direct oral anticoagulants (DOAC) now provide further therapeutic options, generalisability of trial evidence across the spectrum of older people may be limited as they excluded people anticipated to be in the last one to two years of life and those with several co-morbidities [17-20].

The objective of this review is to synthesise the existing evidence base on the association between frailty, AF and clinical outcomes, with a particular focus on OAC.

Methods

The review was conducted according to meta-analysis of observational studies in epidemiology (MOOSE) guidelines, and reported using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) recommendations [21, 22].

Protocol and registration

The review protocol is registered with PROSPERO (CRD42018092951) [23].

Eligibility criteria

Studies that used a validated measure to identify frailty in populations with AF (permanent, paroxysmal or persistent) or atrial flutter were considered eligible. Reviews, case reports, case series and conference proceedings were excluded. Studies were limited to those in the English language.

Information sources

We searched CINAHL, Cochrane, Embase, Medline and Web of Science from inception of each until October 2017. The search strategy was developed with a research librarian (Supplementary data, available in *Age and Ageing* online).

Study selection

Two independent reviewers (C.W. and O.T.) screened titles and abstracts for potentially eligible studies, and assessed full-text articles against the eligibility criteria. All disagreements were resolved through consensus. Reasons for exclusion of articles at the full-text review stage were collated using Covidence [24].

Data extraction

Data from the included studies was extracted using a pro forma including author, year of publication, study period, study design, country, setting, patient characteristics (age, sex, prevalence of co-morbidities, ethnicity), frailty measure, AF prevalence and outcomes assessed. Where frailty status was dichotomised, the threshold used by the study author was used. Data for meta-analysis were extracted by two independent reviewers (C.W. and O.T.).

Outcomes

The primary outcome was OAC prescription by frailty status. Secondary outcomes included: ischaemic and haemorrhagic stroke; all-cause mortality; disability; care home admission; hospitalisation and haemorrhagic events.

Risk of bias in individual studies

The Newcastle–Ottawa checklist was used by two authors (C.W. and O.T.) to independently assess risk of bias [25, 26], with an adapted scale for cross-sectional studies [27]. Studies were assessed on the domains of selection, comparability, exposure and outcome. Studies rated as moderate or good were considered as having low risk of bias.

Synthesis of results

Two authors (C.W. and O.T.) extracted adjusted odds ratios (ORs) with 95% CIs for dichotomous data. OR for frail versus non-frail were used; when the reverse was reported by the authors then an inverse OR was calculated. We synthesised data for meta-analysis by generic inverse variance random-effects modelling summarised as an OR using RevMan 5.3 software [28]. Random-effects

C. Wilkinson et al.




Figure 1. PRISMA diagram of included studies

modelling was selected because we anticipated that the classification of frailty status may be based on different instruments, and to allow for clinical heterogeneity. Adjusted data were prioritised because they account for confounding variables and are considered more reliable. Unadjusted ORs were not included in the meta-analysis.

Results

Study selection

The review is summarised in Figure 1. The search identified 1,839 studies, of which 165 were retrieved for full-text review. Of these, 20 met the eligibility criteria and are

Study	Setting	Age criteria	Mean [median] age	Country	Measure of frailty	n	Overall risk of bias
Prospective cross-sectional							
Bo (2015) [31]	Hospital	≥ 65	81.7	Italy	GFI	513	Low
Denoël (2014) [34]	Hospital	≥75	NR	Belgium	ISAR	995	Low
Donoghue (2014) [35]	Community	≥50	70.7	Republic of Ireland	GU&G, Gait speed	4,525	Low
Frewen (2013) [47]	Community	≥ 50	63.8	Republic of Ireland	Fried criteria	4,890	Low
Hess (2013) [40]	Outpatients	≥18	[75]	The USA	Fried criteria	10,096	Low
Hung (2013) [36]	Hospital	≥75	[75]	Taiwan	GU&G	401	Low
Mlynarska (2017) [37]	Hospital	none	72.7	Poland	TFI	132	Low
O'Caoimh (2017) [38]	Nursing home	none	[84]	Republic of Ireland	CFS	225	Low
Polidoro (2013) [39]	Hospital	none	79.3	Italy	Frailty index [59]	140	Low
Retrospective cross-section							
Annoni (2016) [2]	Hospital	≥65	84.6	Italy	Robinson criteria [60]	1,619	Low
Induruwa (2017) [30]	Hospital	≥75	85.3	The UK	CFS	419	Low
Lefebvre (2016) [29]	Hospital	$\geq \! 80$	85.9	Canada	CFS	682	Low
Prospective cohort studies							
Bo (2017) [41]	Hospital	≥65	81.6	Italy	GFI	452	Low
Doucet (2008) [42]	Hospital	>65	84.7	France	GU&G	209	Moderate
Gullón (2017) [43]	Hospital	>75	85	Spain	FRAIL scale	804	Low
Magnani (2016) [44]	Community	70-79	N/A	The USA	Health ABC battery	2,753	Low
Nguyen (2016) [32]	Hospital	≥65	84.7	Australia	Reported EFS	302	Low
Nguyen (2016) [45]	Hospital	≥65	84.7	Australia	Reported EFS	302	Low
Perera (2009) [3]	Hospital	≥70	82.7	Australia	Modified EFS	207	Low
Retrospective cohort study	1						
Pilotto (2016) [46]	Community, previous hospitalisation	≥65	84.4	Italy	MPI	1,287	Low

Table I. Summary of included studies

Abbreviations: EFS, Edmonton Frail Scale; GFI, Groningen frailty indicator; GU&G, get-up-and-go test; MPI, multidimensional prognostic index; MPI-SVaMA, MPI based on standardised multidimensional assessment schedule for adults and aged persons; NR, not reported; TFI, Tilburg Frailty Index. Further detail in Supplementary Table S2.

included in this review; 6 within a meta-analysis [3, 29–33] and 14 in a narrative synthesis [2, 34–46]. All were observational studies.

Study characteristics

Twelve cross-sectional [2, 29–31, 33–40] and eight cohort studies were included [3, 32, 41–46], with a total of 30,883 participants (Table 1). Fifteen studies were based in hospital [2, 3, 29–32, 34, 36, 37, 39, 41–43, 45, 46], and five were communitybased [33, 35, 38, 40, 44], one of which involved nursing home residents [38]. Thirteen studies were conducted in Europe [2, 30, 31, 33–35, 37–39, 41–43, 46], three in Australia [32, 38, 45], three in North America [29, 40, 44] and one in Taiwan [36].

Risk of bias within studies

Overall, the included studies were moderate to low risk of bias (Supplementary Table S3). The six studies included in the metaanalysis were judged at low risk of bias overall, with risk identified in two studies regarding ascertainment of outcome [3] and follow-up duration [3, 32]. However, these did not relate to the specific meta-analysis question of OAC and frailty associations.

Participant characteristics

Amongst patients with AF the mean age was 83.3 years (reported in 16 studies [2, 3, 29–32, 35–37, 39, 42, 43, 45–47]),

range 58–101 years (6 studies [30, 32, 39, 42, 43, 45]) and 48.2% female (18 studies [2, 3, 29–33, 35–43, 45, 46]). Excluding a large registry of outpatients [40], 56.8% of participants were female.

Eight studies also included patients without AF [2, 34–36, 38, 39, 44, 47]. The mean age of the whole cohort (those with AF and those without) was 68.5 years (reported in six studies [2, 35, 36, 39, 44, 47]), range 56–96 (two studies [35, 39]). 50.3% were female (seven studies [2, 35, 36, 38, 39, 44, 47], Supplementary Table S2).

Assessment of frailty

Of the thirteen measures of frailty used, the timed-upand-go test [48], clinical frailty scale [49] and Edmonton frail scale [50] were most common (three studies each, Table 1).

Prevalence of AF

AF prevalence was reported in six studies, but not stratified by frailty status [2, 33–36, 38]. It varied by setting from 3% in community-dwellers [33, 35], to 38% in nursing home residents [38]. In three studies of older patients admitted acutely to hospital, AF was identified in 14% [34], 17% [36] and 24% [2] (Supplementary Table S2).

AF and frailty

Sixteen studies reported the prevalence of frailty in patients with AF [2, 3, 29–32, 34, 36–41, 43, 45, 46]. This varied between populations, affecting 6% in a registry of outpatients aged \geq 18 [40], and 100% in a nursing home population (Supplementary Table S4) [38]. In older people admitted to hospital, AF was strongly associated with being frail (adjusted OR 4.09, 95% CI 1.51–11.07, adjusted for age, sex, hypertension, diabetes, stroke, myocardial infarction and heart failure) [39].

Hung *et al.* found that whilst there was no difference in frailty between those admitted to a geriatric unit with AF and without, AF was an independent risk factor for falls (adjusted OR 1.98 [95%CI 1.08–3.63], adjusted for benzodiazepine use, paroxysmal subgroup of AF, hypertension, polypharmacy and age) [36]. However, the tendency to fall may have increased AF case-detection through use of ambulatory electrocardiography. Magnani *et al.* showed that age-related decline in physical performance in communitydwellers was accelerated by approximately \sim 4 years for those with AF compared with those without [44].

AF, frailty and anticoagulation

Hospital cohorts

Eight studies were in a hospitalised population with AF (Table 2) [3, 29–32, 34, 41, 42]. Five were methodologically similar, reported adjusted OR for the association between frailty and OAC, and were included in the meta-analysis (Figure 2) [3, 29–32]. Two studies reported OR at admission [29, 30], and two at discharge [31, 32]. One study reported both [3].

At hospital admission: meta-analysis showed that people with frailty had lower odds of OAC prescription than those without frailty (pooled adjusted OR 0.45 [95%CI 0.22–0.93]) [3, 29, 30]. One study reported an unadjusted OR, and was

Table 2. Studies reporting the association between frailty and anticoagulation status

Study	Association: frailty and OAC prescription	Time of assessment	n	Unadjusted OR (95% CI)	Adjusted OR (95% CI)
Lefebvre (2016) [29]	Less use	Hospital admission	682	0.45 (0.31–0.65)	0.29 (0.16–0.54)
Induruwa (2017) [30]	Less use	Hospital admission	419	NR	0.77 (0.70-0.85)
Perera (2009) [3]	Less use	Hospital admission	220	NR	0.34 (0.17-0.68)
		Hospital discharge	220	NR	0.12 (0.06-0.23)
Denoël (2014) [34]	No difference	Hospital admission	142	OR 1.12 (0.50-2.96)	NR
Bo (2015) [31]	No difference	Hospital discharge	430	NR	0.80 (0.41-1.57)
Nguyen (2016) [32]	No difference	Hospital discharge	302	0.58 (0.36-0.93)	0.66 (0.40-1.10)
Doucet (2008) [42]	No difference	Hospital discharge	209	NR	NR
Frewen (2013) [33]	More use	Community sample	118	NR	2.33 (1.03-5.23)

Abbreviations: NR, not reported; OR, odds ratio. Adjustments detailed in Supplementary Table S5.

Study or Subgroup	Odds Ratio Random, 95% Cl	Odds Ratio IV, Random, 95% CI
At time of admission	Randoni, 55% Ci	
Induruwa	0.77 [0.70, 0.85]	-
Lefebvre	0.29 [0.16, 0.54]	
Perera Subtotal (95% CI)	0.34 [0.17, 0.68] 0.45 [0.22, 0.93]	-
Heterogeneity: $Tau^2 = 0.35$; $Chi^2 = 14.10$, $df = 2$ (F	$P = 0.0009$; $I^{*} = 86\%$	
Test for overall effect: $Z = 2.15$ (P = 0.03)		
At time of discharge		
Во	0.80 [0.41, 1.57]	
Nguyen	0.66 [0.40, 1.10]	
Perera	0.12 [0.06, 0.23]	
Subtotal (95% CI)	0.40 [0.13, 1.23]	
Heterogeneity: $Tau^2 = 0.88$; $Chi^2 = 19.88$, $df = 2$ (f	$P < 0.0001$; $l^2 = 90\%$	
Test for overall effect: $Z = 1.59$ (P = 0.11)		
Community		
Frewen	2.33 [1.03, 5.23]	
Subtotal (95% CI)	2.33 [1.03, 5.23]	
Heterogeneity: Not applicable		-
Test for overall effect: $Z = 2.04$ (P = 0.04)		
All studies included in the meta-analysis were judge	ad at low risk of bias	
An studies included in the meta-analysis were judge	0.0	01 0.1 1 10 100
	_	ve association +ve association

Figure 2. Forest plot to show association between frailty and anticoagulation status at admission, at discharge and in the community

not included in the meta-analysis. This showed no association between OAC prescription and frailty (unadjusted OR 1.12 [0.50–2.96]) [34]. The later was a small study using a brief screening tool with limited predictive validity (Identifying Seniors at Risk) [51].

At hospital discharge: meta-analysis showed that frailty had no statistically significant association with OAC prescription (pooled adjusted OR 0.40 [95% CI 0.13–1.23]) [3, 31, 32]. One study used propensity score analysis and whilst it was not included in the meta-analysis, it also found no association between frailty and OAC prescription after matching [41].

Community cohorts

In contrast to the hospital cohorts, a study using a nationally representative community sample found that people with frailty had an increased odds of OAC prescription compared with people without frailty (adjusted OR 2.33 [95%CI 1.03–5.23], adjusted for age, sex and education) [47].

In a study of nursing home residents with AF and frailty, 70% of participants were eligible for OAC according to a bespoke risk based decision-support aid incorporating stroke and bleeding risk [38]. However, just 17% were prescribed OAC. A separate study found that advanced age, very short life expectancy, difficult/impossible management of therapy, fear of bleeding and harm greater than benefit were commonly reported reasons for not prescribing OAC in older patients [31].

DOAC use

Across five studies, DOAC was prescribed in between 5.4% and 20.6% of those anticoagulated [29–32, 43]. This was stratified by frailty status in one study, but it only included 11 patients on DOAC [30].

Age, co-morbidity and anticoagulation

Six studies reported the association between increasing age and OAC prescription [29–32, 42, 47], five of which adjusted for other factors (Supplementary Table S5) [29–32, 47]. Increased age was independently associated with reduced OAC prescription in four studies (adjusted OR range 0.71 [0.59–0.84]–0.98 [0.97–0.98]) [29–32], but not in the fifth (adjusted OR 1.02 [0.97–1.07]) [47]. Finally, a study published in 2008 showed patients prescribed antiplatelet medications instead of OAC tended to be older (mean 86.5 vs. 82.9 years, P < 0.01) [42].

Two studies reported the association between Charlson co-morbidity score and OAC prescription. One showed that an increased adjusted score was independently associated with not being prescribed OAC [31]. The second showed no statistically significant difference in score between those prescribed OAC and those that were not [34].

Anticoagulation and outcomes

One study noted a greater incidence of cardio-embolic stroke among individuals with frailty compared with those without frailty (12.3% vs. 3.9%, P < 0.05). However, the incident cases of stroke were not stratified by OAC prescription due to a small number of events [3]. Patients with AF and frailty also had a higher 6-month mortality compared with those with AF without frailty (unadjusted RR 2.8 [95%CI 1.2–6.5]) [3]. Nguyen *et al.* showed no difference in stroke or major bleeding by frailty status in patients with AF, which the authors suggest may be related to careful patient selection and OAC management [32].

Doucet *et al.* found no difference in clinical outcomes (stroke, death, major bleeding) at 3 months between patients with AF who were prescribed OAC compared with an antiplatelet [42]. The prevalence of falls post-discharge was higher in the aspirin compared with the OAC group (18.6% vs. 7.5%, P < 0.02) despite similar pre-admission falls history. This may suggest that clinicians were aware of an increased falls risk in these individuals that was not captured by the study. Physicians tended to overestimate the risk of bleeding, and underestimate the risk of thrombosis compared with objective scores.

Frailty and mortality in AF

Three studies report the association between frailty and mortality in patients with AF. However, the different representations of risk and durations of follow-up did not allow pooling for meta-analysis. Perera et al. identified increased mortality in patients with AF and frailty compared with patients with AF but not frailty (unadjusted RR 2.8 [95%CI 1.2-6.5]) [3]. Nguyen et al. report increased 6month mortality associated with frailty, (adjusted HR 2.33 [95%CI 1.31-4.14], adjusted for age, gender, co-morbidity, CHAD₂DS₂-VASc, HAS-BLED, delirium, OAC, digoxin or psychotropic medication) and that length of stay was 3.1 days longer in individuals with frailty compared with those without [45]. During a mean follow-up period of 301 days, Bo et al. found that in patients with AF, frailty was associated with an increased risk of mortality compared with non-frail patients (adjusted OR 2.77 [95% CI 1.44-5.33], adjusted for OAC, ADL dependence, serum albumin and readmission) [41]. A further study found that functional status, but not frailty (FRAIL scale), was independently associated with inpatient mortality [43].

Discussion

This systematic review included 20 research articles published between 2013 and 2017. Six studies were included in a meta-analysis of the association between frailty status and OAC prescription in patients with AF. At hospital admission, frailty was associated with decreased OAC prescription, but there was no statistically significant association at discharge. A community-based study found that frailty was associated with increased OAC prescription.

We report evidence that in patients with AF, frailty is associated with increased stroke incidence [3], mediumterm mortality [3, 45], symptom severity [37] and length of hospital stay [45]. One study showed frailty was not associated with stroke or major bleeding [32]. Having AF was associated with a greater chance of being frail [39], having falls [36] and physical performance decline [44] compared with people without AF, suggesting that AF itself may be a marker of frailty. There was a lack of data on clinical outcomes stratified by both frailty and OAC status [3, 32, 42].

The different association between frailty and OAC prescription among hospital and community cohorts was striking. The findings at hospital admission are reflective of prescribing patterns in the community, albeit in a subgroup who have been hospitalised, with potential for different characteristics. The absence of a statistically significant association between OAC prescription and frailty status at discharge may be because hospitalisation allowed more complete case ascertainment and prescription of therapy. However, survivorship bias is also a potential factor, whereby fitter patients are more likely to survive to discharge. Furthermore, hospitalisation in the context of frailty is a potential marker of nearing end of life, so deprescribing decisions could be influenced accordingly [52].

In a community study with a relatively young population and low AF prevalence, frailty was associated with an increased OAC prescription rate [47]. In contrast, in a nursing home population with a relatively high prevalence, just 25% of the eligible population were prescribed OAC [38]. Competing risks are likely to be influencing prescribing behaviour in this vulnerable population.

There are concerns that clinical guidelines tend to relate to single-organ pathology [10, 13], and the trial evidence on which they are based frequently excludes people with frailty, including of DOACs [17-20]. Furthermore, CHA₂DS₂-VASc has not been validated for use in the oldest old or people with frailty [53]. In the absence of trial evidence, observational data can offer insights into current practice and patient outcomes. However, this review identified a lack of research in a community setting using validated frailty measures, despite growing evidence that a greater mortality risk is carried by measures of biological than chronological age [9, 54]. There is therefore a limited evidence base to guide management in this high-risk population in whom bleeding complications may be more common and more problematic than in the general population [16, 55]. A risk-treatment paradox exists, whereby those at the highest risk of stroke are not more likely to receive anticoagulation [6, 56]. Whether frailty should influence OAC prescribing, including through incorporation into AF decision-support tools, is currently unknown.

Strengths of the review

To our knowledge, this is the first systematic review to summarise current evidence for the management of AF in older people with frailty. We have used a robust search strategy, risk of bias assessment and methods pre-specified in a published protocol. We were able to present pooled adjusted estimates of the association between OAC pre-scription and frailty, and included data on DOAC use, reflecting recent trends. However, the small proportion of patients that were taking DOAC in the included studies despite its increasing role reinforces the need for contemporary research [57].

Limitations of the review

A range of frailty measures was used and frailty was dichotomised as in the source study. This may introduce additional heterogeneity in the meta-analysis. Whilst we have reported OAC prescription at different time points, this was without access to individual patient data, so we cannot exclude misclassification error. Frailty was often diagnosed in an acute hospital setting, although guidance suggests frailty assessment is best performed in the community [58]. Most studies excluded patients with cognitive or major sensory impairment due to the necessity for informed consent, and so may not be representative of the overall frail population. Some studies required participants to complete a physical task, which may exclude those with advanced frailty. There was variation in the choice of confounders in the adjusted estimates included in our meta-analysis. We have reported adjusted and unadjusted estimates where available, with similar direction of associations.

As with any meta-analysis of observational data there are risks of confounding by indication and other systemic biases that are incompletely accounted for. Further observational data in a community setting with complementary qualitative work would contribute to our understanding of current practice, but with susceptibility to bias. A randomised trial may ultimately be needed to help quantify efficacy and safety endpoints in a frail population.

Conclusion

At hospital admission frailty was associated with decreased OAC prescription. However, there was no statistically significant association at the time of discharge. A single study in a community setting showed that frailty was associated with increased OAC prescription. There is evidence that in patients with AF, frailty is associated with increased stroke incidence, mortality, symptom severity, and length of hospital stay.

Although anticoagulation is largely initiated and managed in primary care, there is a lack of evidence to guide optimal care in this setting for patients with AF and frailty. This may in part explain a gap between current guidelines and clinical practice in management of these patients, particularly in relation to OAC prescription.

Supplementary data mentioned in the text are available to subscribers in *Age and Ageing* online.

Acknowledgements: The authors are grateful to Deidre Andre, Research Librarian at the University of Leeds for assistance with the design of the search strategies.

Declaration of Conflict of Interest: None.

Funding: This work was supported by the Dunhill Medical Trust (RTF107/0117) research training fellowship to OT; Wellcome Trust (206470/Z/17/Z) Sir Henry Wellcome Postdoctoral Fellowship to MH. AC is part-funded by the National Institute for Health Research Collaboration for Leadership in Applied Health Research and Care, Yorkshire & Humber. The funders had no role in the design, execution, analysis or interpretation of the data or writing of the study.

References

- Additional references are available to subscribers in *Age and Ageing* online.
- 2. Annoni G, Mazzola P. Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants? J Geriatr Cardiol 2016; 13: 226–32.
- **3.** Perera V, Bajorek BV, Matthews S, Hilmer SN. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing 2009; 38: 156–62.
- 9. Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet 2013; 381: 752–62.
- **10.** National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management. NICE guideline NG56. 2016.
- **12.** Rich MW, Chyun DA, Skolnick AH *et al.* Knowledge gaps in cardiovascular care of older adults: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society: Executive Summary. J Am Geriatr Soc 2016; 64: 2185–92.
- 14. Morley JE, Vellas B, van Kan GA *et al.* Frailty consensus: a call to action. J Am Med Dir Assoc 2013; 14: 392–7.
- **29.** Lefebvre M-CD, St-Onge M, Glazer-Cavanagh M *et al.* The effect of bleeding risk and frailty status on anticoagulation patterns in octogenarians with atrial fibrillation: the FRAIL-AF study. Can J Cardiol 2016; 32: 169–76.
- **30.** Induruwa I, Evans NR, Aziz A, Reddy S, Khadjooi K, Romero-Ortuno R. Clinical frailty is independently associated with non-prescription of anticoagulants in older patients with atrial fibrillation. Geriatr Gerontol Int 2017; 17: 2178–83.
- **31.** Bo M, Li Puma F, Badinella Martini M *et al.* Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: a prospective observational study. Int J Cardiol 2015; 187: 123–5.
- **32.** Nguyen TN, Cumming RG, Hilmer SN. Atrial fibrillation in older inpatients: are there any differences in clinical characteristics and pharmacological treatment between the frail and the non-frail? Intern Med J 2016; 46: 86–95.
- 33. Frewen J, Finucane C, Cronin H et al. Factors that influence awareness and treatment of atrial fibrillation in older adults. QJM. J Med 2013; 106: 415–24.

- **34.** Denoel P, Vanderstraeten J, Mols P, Pepersack T. Could some geriatric characteristics hinder the prescription of anticoagulants in atrial fibrillation in the elderly? J Aging Res 2014; 2014: 693740.
- **35.** Donoghue OA, Jansen S, Dooley C, De Rooij S, Van Der Velde N, Kenny RA. Atrial fibrillation is associated with impaired mobility in community-dwelling older adults. J Am Med Dir Assoc 2014; 15: 929–33.
- **36.** Hung CY, Wu TJ, Wang KY *et al.* Falls and atrial fibrillation in elderly patients. Acta Cardiol Sin 2013; 29: 436–43.
- 37. Mlynarska A, Mlynarski R, Golba KS. Older age and a higher EHRA score allow higher levels of frailty syndrome to be predicted in patients with atrial fibrillation. Aging Male 2017; 20: 23–7.
- 38. O'Caoimh R, Igras E, Ramesh A, Power B, O'Connor K, Liston R. Assessing the appropriateness of oral anticoagulation for atrial fibrillation in advanced frailty: use of stroke and bleeding risk-prediction models. J Frailty Aging 2017; 6: 46–52.
- **39.** Polidoro A, Stefanelli F, Ciacciarelli M, Pacelli A, Di Sanzo D, Alessandri C. Frailty in patients affected by atrial fibrillation. Arch Gerontol Geriatr 2013; 57: 325–7.
- **40.** Hess PL, Kim S, Piccini JP *et al.* Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillation. Am J Med 2013; 126: 625–32.e1.
- **41.** Bo M, Li Puma F, Martini MB *et al.* Effects of oral anticoagulant therapy in older medical in-patients with atrial fibrillation: a prospective cohort observational study. Aging Clin Exp Res 2017; 29: 491–7.
- **42.** Doucet J, Greboval-Furstenfeld E, Tavildari A *et al.* Which parameters differ in very old patients with chronic atrial fibrillation treated by anticoagulant or aspirin? Antithrombotic treatment of atrial fibrillation in the elderly. Fundam Clin Pharmacol 2008; 22: 569–74.
- **43.** Gullon A, Formiga F, Camafort M *et al.* Baseline functional status as the strongest predictor of in-hospital mortality in elderly patients with non-valvular atrial fibrillation: results of the NONAVASC registry. Eur J Intern Med 2018; 47: 69–74.
- **44.** Magnani JW, Wang N, Benjamin EJ *et al.* Atrial fibrillation and declining physical performance in older adults the health, aging, and body composition study. Circ Arrhythm Electrophysiol 2016; 9: e003525.
- **45.** Nguyen TN, Cumming RG, Hilmer SN. The impact of frailty on mortality, length of stay and re-hospitalisation in older patients with atrial fibrillation. Heart Lung Circ 2016; 25: 551–7.
- **46.** Pilotto A, Gallina P, Copetti M *et al.* Warfarin treatment and all-cause mortality in community-dwelling older adults with atrial fibrillation: a retrospective observational study. J Am Geriatr Soc 2016; 64: 1416–24.
- **47.** Frewen J, Finucane C, Rice C, Kearney P, Kenny RA, Harbison JA. The use of anticoagulation therapy in subjects with atrial fibrillation in the irish longitudinal study of ageing (TILDA). Cerebrovasc Dis 2012; 33: 822–3.
- **52.** Gill TM, Gahbauer EA, Han L, Allore HG. The role of intervening hospital admissions on trajectories of disability in the last year of life: prospective cohort study of older people. BMJ 2015; 350: h2361.
- **54.** Clegg A, Bates C, Young J *et al.* Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing 2016; 45: 353–60.
- **57.** Lacoin L, Lumley M, Ridha E *et al.* Evolving landscape of stroke prevention in atrial fibrillation within the UK between

2012 and 2016: a cross-sectional analysis study using CPRD. BMJ Open 2017; 7: e015363.

- 58. Turner G, Clegg A. Best practice guidelines for the management of frailty: a British Geriatrics Society, Age UK and Royal College of General Practitioners report. Age Ageing 2014; 43: 744–7.
- **59.** Searle SD, Mitnitski A, Gahbauer EA, Gill TM, Rockwood K. A standard procedure for creating a frailty index. BMC Geriatr 2008; 8: 24.

Received 29 May 2018; editorial decision 8 October 2018

Age and Ageing 2019; **48:** 204–212 doi: 10.1093/ageing/afy186 Published electronically 27 December 2018 © The Author(s) 2018. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com

The prevalence of non-communicable disease in older people in prison: a systematic review and meta-analysis

David Munday¹, Jane Leaman², Éamonn O'Moore², Emma Plugge³

¹Nuffield Department of Population Health, Oxford School of Public Health, University of Oxford, OX3 7LG, UK ²National Health and Justice Team, Public Health England and UK Collaborating Centre, WHO Health in Prisons Programme, Premier House, Reading, RG1 7EB, UK

³Nuffield Department of Clinical Medicine, Centre for Tropical Medicine and Global Health, University of Oxford, OX3 7LG, UK

Address correspondence to: David Munday, Public Health Specialty Registrar, c/o Training Programme Officer, Oxford School of Public Health, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Old Road Campus, Headington, Oxford, OX3 7LG, UK. Email: davidmunday@nhs.net

Abstract

Background: people in prison often experience poor health. Those aged 50 and over are the fastest growing age-group in prison and present particular challenges to criminal justice systems around the world. Non-communicable diseases (NCDs) account for two-thirds of deaths globally and no estimate of the prevalence of NCDs in this vulnerable population exists.

Methods: we searched PubMed, Medline, CINAHL, EMBASE and Global Health databases to identify original research papers that met our pre-defined inclusion criteria. No date or language restrictions were applied. Two authors undertook full-text screening as well as quality assessment and data extraction for all included studies. A random effects model was used to calculate pooled prevalence of any disease that was reported in two or more articles.

Results: the initial search identified 2,712 articles. 119 underwent full-text screening with 26 meeting the inclusion criteria. This provided prevalence data on 28 NCDs in 93,862 individuals from prisons in 11 countries. Pooled prevalence for the most significant NCDs was a follows; cancer 8% (95% CI 6–10%), cardiovascular disease 38% (95% CI 33–42%), hypertension 39% (95% CI 32–47%), diabetes 14% (95% CI 12–16%), COPD prevalence estimates ranged from 4% to 18%. Heterogeneity across studies was high.

Conclusions: those in prison over 50 years of age experience a high burden of NCDs which is often higher than younger prison and age-matched community peers. This health inequality is influenced by lifestyle, environmental and societal factors. Prison services should be adapted to serve the needs of this growing population.

Keywords

non-communicable Disease (NCDs), older people, prison, prevalence, systematic review